Brii Biosciences introduces BRiSC platform for dual targeting siRNA drugs
Biotechnology company Brii Biosciences launched its proprietary BRiSC discovery platform to accelerate development of next generation dual targeting small interfering RNA therapeutic candidates
DURHAM, N.C. and BEIJING, Oct. 15, 2026 - Brii Biosciences Limited, a biotechnology company focused on developing therapies for diseases with unmet medical needs, has unveiled BRiSC™ (Bispecific RNAiSilenCing), a novel platform for the discovery and development of next-generation RNA-based therapies. This platform combines four key technologies for optimizing sequences, modifying chemicals, designing dual-targeting structures, and implementing targeted delivery methods.
The aim is to improve the selectivity, efficacy, and therapeutic potential of siRNA medicines, enabling the creation of unique treatments for various diseases. Brii Bio has bolstered its internal research and development through investments, laboratory expansions in Beijing and Shanghai, and enhanced RNA technology capabilities, all contributing to the advancement of BRiSC™.
The dual-targeting architecture of BRiSC™ allows a single siRNA therapeutic to simultaneously suppress two different targets, addressing diseases governed by multiple biological pathways through a single treatment. This approach is particularly beneficial for prevalent diseases with complex biology and overlapping comorbidities.
Dr. Brian Johns, Chief Science Officer at Brii Bio, emphasized the company's dedication to developing differentiated RNA therapeutics that can deliver broader benefits to patients by addressing conditions driven by multiple pathways. Additional information is available at www.briibio.com.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
